AR031674A1 - Composicion farmaceutica que comprende un sensibilizador de insulina en combinacion con otro compuesto farmaceuticamente activo y uso de dicho sensibilizador en combinacion con otro compuesto farmaceuticamente activo para fabricarla - Google Patents

Composicion farmaceutica que comprende un sensibilizador de insulina en combinacion con otro compuesto farmaceuticamente activo y uso de dicho sensibilizador en combinacion con otro compuesto farmaceuticamente activo para fabricarla

Info

Publication number
AR031674A1
AR031674A1 ARP000104514A ARP000104514A AR031674A1 AR 031674 A1 AR031674 A1 AR 031674A1 AR P000104514 A ARP000104514 A AR P000104514A AR P000104514 A ARP000104514 A AR P000104514A AR 031674 A1 AR031674 A1 AR 031674A1
Authority
AR
Argentina
Prior art keywords
formula
compound
salt
pharmaceutical composition
combination
Prior art date
Application number
ARP000104514A
Other languages
English (en)
Spanish (es)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR031674A1 publication Critical patent/AR031674A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000104514A 1999-09-03 2000-08-30 Composicion farmaceutica que comprende un sensibilizador de insulina en combinacion con otro compuesto farmaceuticamente activo y uso de dicho sensibilizador en combinacion con otro compuesto farmaceuticamente activo para fabricarla AR031674A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP2000056021 2000-02-28

Publications (1)

Publication Number Publication Date
AR031674A1 true AR031674A1 (es) 2003-10-01

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104514A AR031674A1 (es) 1999-09-03 2000-08-30 Composicion farmaceutica que comprende un sensibilizador de insulina en combinacion con otro compuesto farmaceuticamente activo y uso de dicho sensibilizador en combinacion con otro compuesto farmaceuticamente activo para fabricarla

Country Status (14)

Country Link
EP (1) EP1212090A2 (pl)
KR (1) KR20020063555A (pl)
CN (1) CN1372476A (pl)
AR (1) AR031674A1 (pl)
AU (1) AU6868000A (pl)
CA (1) CA2383946A1 (pl)
CO (1) CO5180632A1 (pl)
HK (1) HK1044711A1 (pl)
HU (1) HUP0203285A3 (pl)
NO (1) NO20021036L (pl)
PE (1) PE20010580A1 (pl)
PL (1) PL354295A1 (pl)
RU (1) RU2002108346A (pl)
WO (1) WO2001017513A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341343T1 (de) 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
CA2443325C (en) 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
CA2488699A1 (en) 2002-06-12 2003-12-24 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4649189A (en) * 1988-11-14 1990-06-12 Upjohn Company, The Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
DK0514452T4 (da) * 1990-02-09 2000-09-18 Upjohn Co Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
PT801059E (pt) * 1994-11-29 2001-10-30 Dainippon Pharmaceutical Co Derivado indol

Also Published As

Publication number Publication date
HUP0203285A2 (hu) 2003-01-28
KR20020063555A (ko) 2002-08-03
PL354295A1 (pl) 2004-01-12
RU2002108346A (ru) 2003-11-20
WO2001017513A2 (en) 2001-03-15
NO20021036D0 (no) 2002-03-01
EP1212090A2 (en) 2002-06-12
HUP0203285A3 (en) 2003-02-28
CA2383946A1 (en) 2001-03-15
AU6868000A (en) 2001-04-10
HK1044711A1 (zh) 2002-11-01
CO5180632A1 (es) 2002-07-30
PE20010580A1 (es) 2001-05-25
CN1372476A (zh) 2002-10-02
WO2001017513A3 (en) 2001-09-20
NO20021036L (no) 2002-04-26

Similar Documents

Publication Publication Date Title
NO20074012L (no) 1-tio-D-glucitolderivater
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
JP2010536882A5 (pl)
JP2010506942A5 (pl)
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
AR029469A1 (es) Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
AR069772A1 (es) Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria.
BRPI0707718A2 (pt) uso de um composto
WO2017106306A1 (en) Methods of treating hyperalgesia
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
GEP20094727B (en) Oxyindole derivatives as 5ht4 receptor agonists
Testai et al. Cardiac ATP-sensitive potassium channels: a potential target for an anti-ischaemic pharmacological strategy
Fan et al. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition
US20260027088A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
EP3129375A1 (en) Asparagine endopeptidase (aep) inhibitors for managing cancer and compositions related thereto
PE20241590A1 (es) Derivados del acido 3-fenil-1-benzotiofeno-2-carboxilico como inhibidores de la quinasa deshidrogenasa de alfa cetoacidos de cadena ramificada para el tratamiento de la diabetes, enfermedades renales, nash e insuficiencia cardiaca
IE60707B1 (en) Pharmacologically active substituted benzamides
EP2131845B1 (en) 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms
ES2972934T3 (es) Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
AR072883A1 (es) COMPOSICIoN FARMACÉUTICA SoLIDA CON EL COMPUESTO (5-METIL-2-OXO-1,3-DIOXOL-4-IL)METIL2-ETOXI-1-{[2' -(5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL}-1H-BENCIMIDAZOL-7-CARBOXILATO Y UN DIURÉTICO PARA LA PROFILAXIS O TRATAMIENTO DE ENFERMEDADES DEL APARATO CIRCULATORIO.
JP2007527904A5 (pl)
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
NO20051900L (no) Kinazolinderivater som SRC tyrosin kinase inhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal